

29. Bystroň J. Účinnost léčby anti-IgE monoklonální protilátkou nejen u těžkého alergického astmatu (problémy, skutečnost, naděje). *Alergie*. 2011;13:264-267.
30. Ledford D, Busse WW, Trzaskoma B, et al. A randomized multicenter study evaluating Xolair persistence of response after long-term therapy. *J Allergy Clin Immunol*. 2017;140:162-169.
31. Krčmová I, Novosad J, Malá E, et al. Small, prospective, observational, pilot study in severe asthmatic patients after omalizumab treatment discontinuation. *Clin Ther*. 2018;40:1942-1953.
32. Labrador-Horrillo M, Ferrer M. Profile of omalizumab in the treatment of chronic spontaneous urticaria. *Drug Des Devel Ther*. 2015;9:4909-4915.
33. Wood RA, Togias A, Sicherer SH, et al. Omalizumab for the Treatment of Multiple Food Allergies. *N Engl J Med*. 2024;390:889-99.
34. Wenzel SE. Eosinophils in Asthma — Closing the Loop or Opening the Door? *N Engl J Med*. 2009;360:1026-1028.
35. Pavord ID, Korn S, Howarth P, et al. Mepolizumab for severe eosinophilic asthma (DREAM): A multicentre, double-blind, placebo-controlled trial. *Lancet*. 2012;380:651-659.
36. Ortega HG, Liu MC, Pavord ID, et al. Mepolizumab Treatment in Patients with Severe Eosinophilic Asthma. *N Engl J Med*. 2014;371:1198-1207.
37. Bel EH, Wenzel SE, Thompson PJ, et al. Oral glucocorticoid-sparing effect of mepolizumab in eosinophilic asthma. *N Engl J Med*. 2014;371:1189-1197.
38. Chupp GL, Bradford ES, Albers FC, et al. Efficacy of mepolizumab add-on therapy on health-related quality of life and markers of asthma control in severe eosinophilic asthma (MUSCA): a randomised, double-blind, placebo-controlled, parallel-group, multicentre, phase 3b trial. *Lancet Respir Med*. 2017;5:390-400.
39. Han JK, Bachert C, Fokkens W, et al. Mepolizumab for chronic rhinosinusitis with nasal polyps (SYNAPSE): a randomised, double-blind, placebo-controlled, phase 3 trial. *Lancet Respir Med*. 2021;9:1141-1153.
40. Roufosse F, Kahn J-E, Rothenberg ME, et al. Efficacy and safety of mepolizumab in hypereosinophilic syndrome: A phase III, randomized, placebo-controlled trial. *J Allergy Clin Immunol*. 2020;146:1397-1405.
41. Wechsler ME, Akuthota P, Jayne D, et al. Mepolizumab or Placebo for Eosinophilic Granulomatosis with Polyangiitis. *N Engl J Med*. 2017;376:1921-1932.
42. Moiseev S, Zagvozdina E, Kazarina V, et al. Mepolizumab in patients with eosinophilic granulomatosis with polyangiitis. *J Allergy Clin Immunol*. 2019;144:621.
43. Bettiol A, Urban ML, Dagna L, et al. Mepolizumab for Eosinophilic Granulomatosis With Polyangiitis: A European Multicenter Observational Study. *Arthritis Rheumatol*. 2022;74:295-306.
44. Orecchia M, Welbeck K, Dexter J, et al. Generation and preclinical assessment of depemokimab, an enhanced IL-5 antagonist monoclonal antibody. *Heliyon*. 2026;12:e44247.
45. Singh D, Fuhr R, Bird NP, et al. A Phase 1 study of the long-acting anti-IL-5 monoclonal antibody GSK3511294 in patients with asthma. *Br J Clin Pharmacol*. 2022;88:702-712.
46. Jackson DJ, Wechsler ME, Jackson DJ, et al. Twice-Yearly Depemokimab in Severe Asthma with an Eosinophilic Phenotype. *N Engl J Med*. 2024;391:2337-2349.
47. Nolasco S, Crimi C. Depemokimab, the first ultra-long-acting anti-IL-5 monoclonal antibody for severe eosinophilic asthma. *Med*. 2024;5:1452-1455.
48. Kolbeck R, Kozhich A, Koike M, et al. MEDI-563, a humanized anti-IL-5 receptor α mAb with enhanced antibody-dependent cell-mediated cytotoxicity function. *J Allergy Clin Immunol*. 2010;125:1344-1353.
49. Lavoie M, Gossage DL, Gauvreau G, et al. Effects of benralizumab on airway eosinophils in asthmatic patients with sputum eosinophilia. *J Allergy Clin Immunol*. 2013;132:1086-1096.
50. Nowak RM, Parker JM, Silverman RA, et al. A randomized trial of benralizumab, an anti-interleukin 5 receptor α monoclonal antibody, after acute asthma. *Am J Emerg Med*. 2015;33:14-20.
51. Bleecker ER, FitzGerald JM, Chanez P, et al. Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting β_2 -agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trial. *Lancet*. 2016;388:2115-2127.
52. FitzGerald JM, Bleecker ER, Nair P, et al. Benralizumab, an anti-interleukin-5 receptor α monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial. *Lancet*. 2016;388:2128-2141.
53. Goldman M, Hirsch I, Zangrilli JG, et al. The association between blood eosinophil count and benralizumab efficacy for patients with severe, uncontrolled asthma: subanalyses of the Phase III SIROCCO and CALIMA studies. *Curr Med Res Opin*. 2017;33:1605-1613.
54. FitzGerald JM, Bleecker ER, Menzies-Gow A, et al. Predictors of enhanced response with benralizumab for patients with severe asthma: pooled analysis of the SIROCCO and CALIMA studies. *Lancet Respir Med*. 2018;6:51-64.
55. Bleecker ER, Wechsler ME, FitzGerald JM, et al. Baseline patient factors impact on the clinical efficacy of benralizumab for severe asthma. *Eur Respir J*. 2018;52:1800936.
56. Nair P, Wenzel S, Rabe KF, et al. Oral Glucocorticoid-Sparing Effect of Benralizumab in Severe Asthma. *N Engl J Med*. 2017;376:2448-2458.
57. Pelaia C, Vatrella A, Bruni A, et al. Benralizumab in the treatment of severe asthma: Design, development and potential place in therapy. *Drug Des Devel Ther*. 2018;12:619-628.
58. Busse WW, Bleecker ER, FitzGerald JM, et al. Long-term safety and efficacy of benralizumab in patients with severe, uncontrolled asthma: 1-year results from the BORA phase 3 extension trial. *Lancet Respir Med*. 2019;7:46-59.
59. Bourdin A, Chupp G, Jackson DJ, et al. MELTEMI and COLUMBA: 5-Year Comparative Safety Analysis of Benralizumab and Mepolizumab. *J Allergy Clin Immunol Pract*. 2024;12:2074-2083.e4.
60. Mattioli I, Urban ML, Padoan R, et al. Mepolizumab versus benralizumab for eosinophilic granulomatosis with polyangiitis (EGPA): A European real-life retrospective comparative study. *J Autoimmun*. 2025;153:103398.
61. Wenzel S, Ford L, Pearlman D, et al. Dupilumab in Persistent Asthma with Elevated Eosinophil Levels. *N Engl J Med*. 2013;368:2455-2466.
62. Rabe KF, Nair P, Brusselle G, et al. Efficacy and Safety of Dupilumab in Glucocorticoid-Dependent Severe Asthma. *N Engl J Med*. 2018;378:2475-2485.
63. Castro M, Corren J, Pavord ID, et al. Dupilumab Efficacy and Safety in Moderate-to-Severe Uncontrolled Asthma. *N Engl J Med*. 2018;378:2486-2496.
64. Wenzel S, Castro M, Corren J, et al. Dupilumab efficacy and safety in adults with uncontrolled persistent asthma despite use of medium-to-high-dose inhaled corticosteroids plus a long-acting β_2 agonist: a randomised double-blind placebo-controlled pivotal phase 2b dose-ranging trial. *Lancet*. 2016;388:31-44.
65. Weinstein SF, Katial R, Jayawardena S, et al. Efficacy and safety of dupilumab in perennial allergic rhinitis and comorbid asthma. *J Allergy Clin Immunol*. 2018;142:171-177.
66. Simpson EL, Bieber T, Guttman-Yassky E, et al. Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis. *N Engl J Med*. 2016;375:2335-2348.
67. Blauvelt A, de Bruin-Weller M, Gooderham M, et al. Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blind, placebo-controlled, phase 3 trial. *Lancet*. 2017;389:2287-2303.
68. Busse WW, Maspero JF, Rabe KF, et al. Liberty Asthma QUEST: Phase 3 Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate Dupilumab Efficacy/Safety in Patients with Uncontrolled, Moderate-to-Severe Asthma. *Adv Ther*. 2018;35:737-748.
69. Bachert C, Han JK, Desrosiers M, et al. Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (LIBERTY NP SINUS-24 and LIBERTY NP SINUS-52): results from two multicentre, randomised, double-blind, placebo-controlled, parallel-group phase 3 trials. *Lancet*. 2019;394:1638-1650.
70. Yosipovitch G, Mollanazar N, Ständer S, et al. Dupilumab in patients with prurigo nodularis: two randomized, double-blind, placebo-controlled phase 3 trials. *Nat Med*. 2023;29:1180-1190.
71. Dellon ES, Rothenberg ME, Collins MH, et al. Dupilumab in Adults and Adolescents with Eosinophilic Esophagitis. *N Engl J Med*. 2022;387:2317-2330.
72. Gauvreau GM, O'Byrne PM, Boulet L-P, et al. Effects of an Anti-TSLP Antibody on Allergen-Induced Asthmatic Responses. *N Engl J Med*. 2014;370:2102-2110.
73. Takai T. TSLP Expression: Cellular Sources, Triggers, and Regulatory Mechanisms. *Allergol Int*. 2012;61:3-17.
74. Dahlén S-E. TSLP in Asthma — A New Kid on the Block? *N Engl J Med*. 2014;370(22):2144-2445.
75. Menzies-Gow A, Corren J, Bourdin A, et al. Tezepelumab in Adults and Adolescents with Severe, Uncontrolled Asthma. *N Engl J Med*. 2021;384:1800-1809.
76. Wechsler ME, Colice G, Griffiths JM, et al. SOURCE: a phase 3, multicentre, randomized, double-blind, placebo-controlled, parallel group trial to evaluate the efficacy and safety of tezepelumab in reducing oral corticosteroid use in adults with oral corticosteroid dependent asthma. *Respir Res*. 2020;21:1-10.
77. Wechsler ME, Menzies-Gow A, Brightling CE, et al. Evaluation of the oral corticosteroid-sparing effect of tezepelumab in adults with oral corticosteroid-dependent asthma (SOURCE): a randomised, placebo-controlled, phase 3 study. *Lancet Respir Med*. 2022;10:650-660.
78. Jackson DJ, Lugogo NL, Gurnell M, et al. Oral corticosteroid reduction and discontinuation in adults with corticosteroid-dependent, severe, uncontrolled asthma treated with tezepelumab (WAYFINDER): a multicentre, single-arm, phase 3b trial. *Lancet Respir Med*. 2026;14:129-140.
79. Menzies-Gow A, Ponnarambil S, Downie J, et al. DESTINATION: a phase 3, multicentre, randomized, double-blind, placebo-controlled, parallel-group trial to evaluate the long-term safety and tolerability of tezepelumab in adults and adolescents with severe, uncontrolled asthma. *Respir Res*. 2020;21:1-10.
80. Kelsen SG, Agache IO, Soong W, et al. Astegolimab (anti-ST2) efficacy and safety in adults with severe asthma: A randomized clinical trial. *J Allergy Clin Immunol*. 2021;148:790-798.
81. Wechsler ME, Ruddy MK, Pavord ID, et al. Efficacy and Safety of Itepekimab in Patients with Moderate-to-Severe Asthma. *N Engl J Med*. 2021;385:1656-1668.
82. Corren J, Reid F, Moate R, et al. S90 FRONTIER-3: a randomized, phase 2a study to evaluate the efficacy and safety of tozorakimab (an anti-interleukin-33 monoclonal antibody) in early-onset asthma. *Thorax*. 2024;79:A65-A66.